1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
Hormone Receptor (HR)-positive/ Human Epidermal Receptor 2 (HER2)-negative Breast Cancer- Epidemiology Forecast–2028

Hormone Receptor (HR)-positive/ Human Epidermal Receptor 2 (HER2)-negative Breast Cancer- Epidemiology Forecast–2028

  • September 2019
  • 100 pages
  • ID: 5812510
  • Format: PDF
  • By Delve Insight

Summary

Table of Contents

‘Hormone Receptor (HR)-positive/ Human Epidermal Receptor 2 (HER2)-negative Breast Cancer- Epidemiology Forecast–2028 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Hormone Receptor (HR)-positive/ Human Epidermal Receptor 2 (HER2)-negative Breast Cancer in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Geography Covered 
• The United States 
• EU5 (Germany, France, Italy, Spain, and the United Kingdom) 
• Japan 
 
Study Period: 2017–2028 

Hormone Receptor (HR)-positive/ Human Epidermal Receptor 2 (HER2)-negative Breast Cancer– Disease Understanding 

HR-positive/HER2-negative breast cancer is the most common form of breast cancer. This type accounts for a higher percentage of all breast cancers. Hormone receptors are proteins that receive hormone signals and tell the cancer cells to grow. If breast cancer cells get signals from the hormone estrogen that could promote tumor growth, it is known as estrogen receptor-positive (ER+) breast cancer. If cancerous cells get signals from the hormone progesterone that could promote growth, it is known as progesterone receptor-positive (PR+) breast cancer. Breast cancer that is ER-positive or PR-positive falls under the category of hormone receptor-positive (HR+) breast cancer. Addition to this, there is another factor which is also responsible for breast cancer which is known as human epidermal growth factor receptor 2 (HER2). Human epidermal growth factor receptor-2 is a gene that helps control how cells grow, divide, and repair themselves. There are more number of cases for breast cancer in women observed in comparison to the men. 

Hormone Receptor (HR)-positive/ Human Epidermal Receptor 2 (HER2)-negative Breast Cancer– Epidemiology 
The HR-positive/HER2-negative epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken. 

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented by Total Incidence of Breast Cancer in the 7MM, Incidence of Breast Cancer Cases by Menopausal Status in the 7MM, Incidence of Breast Cancer Cases by Menopausal Status in the 7MM, Stage Specific Incidence of Breast Cancer in Post-Menopausal Women in the 7MM, Stage Specific Incidence of Breast Cancer in Post-Menopausal Women in the 7MM, Diagnosed Incidence of Early Stage Breast Cancer in Post menopause by Molecular Subtype in the 7MM and Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Postmenopause by Molecular Subtype in the 7MM] of HR-positive/HER2-negative in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2017 to 2028. 

According to epidemiology model for HR-positive/ HER2-negative Breast Cancer has assessed that total incident population of Breast Cancer in the 7MM is expected to grow at CAGR of 0.83%, during study period [2017–2028]. estimate suggests the United States show higher incidence of Breast Cancer. As per the estimation, in 2017, among the EU-5 countries, Spain has the least number of breast cancer incident cases. According to the analyst, among the 7MM countries, Japan accounts for the second highest breast cancer incident cases. 
In addition to this according to epidemiology model, based on the menopausal status of women suffering from breast cancer, in the 7MM, the higher number of cases were observed for the postmenopausal Breast cancer, accounting for 70–80% of the cases, while premenopausal women contributed a significantly lesser proportion of the patients. estimates suggests that based on stage-specific incidence of breast cancer in postmenopausal women, Stage IIIb,c and IV-specific breast cancer were observed to be less in number of patients. On the other hand, Stage I-IIIa together accounted for majority of the patient pool. 

Report Scope 
• The report covers detailed overview of HR-positive/ HER2-negative Breast Cancer explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns 
• The report provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the UK) & Japan 
• The Report assesses the disease risk and burden and highlights the unmet needs of HR-positive/ HER2-negative Breast Cancer 
• The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population 
• The report provides the segmentation of the disease epidemiology by type specific cases and severity specific cases of HR-positive/ HER2-negative Breast Cancer in the 7MM 
Catheter-related Bloodstream Infections Report Key Strengths 
• 10 Year Forecast of HR-positive/ HER2-negative Breast Cancer epidemiology 
• 7MM Coverage 
• Total Incidence of Breast Cancer 
• Incidence of Breast Cancer Cases by Menopausal Status 
• Incidence of Breast Cancer Cases by Menopausal Status 
• Stage Specific Incidence of Breast Cancer in Post-Menopausal Women 
• Stage Specific Incidence of Breast Cancer in Post-Menopausal Women 
• Diagnosed Incidence of Early Stage Breast Cancer in Post menopause by Molecular Subtype 
• Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Postmenopause by Molecular Subtype 
Catheter-related Bloodstream Infections Report Assessment 
• Patient Segmentation 
• Disease Risk & Burden 
• Risk of disease by the segmentation 
• Factors driving growth in a specific patient population

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
20% Off

($3250)

  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Receptor Tyrosine Protein Kinase ERBB 3 - Pipeline Review, H2 2019

Receptor Tyrosine Protein Kinase ERBB 3 - Pipeline Review, H2 2019

  • $ 3500
  • August 2019

Receptor Tyrosine Protein Kinase ERBB 3 - Pipeline Review, H2 2019SummaryReceptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 ...

US and European Interventional Oncology Devices Market Assessment for Breast Cancer, Forecast to 2020

US and European Interventional Oncology Devices Market Assessment for Breast Cancer, Forecast to 2020

  • $ 4950
  • September 2019

The research service provides an overview of the interventional oncology devices market for breast cancer in big five countries in Europe and in the United States. The study provides a four-year forecast ...

Mucin 1 - Pipeline Review, H2 2019

Mucin 1 - Pipeline Review, H2 2019

  • $ 3500
  • August 2019

Mucin 1 - Pipeline Review, H2 2019SummaryMucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial ...


ref:plp2019

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on